Fred Saad, MD, FRCS, Highlights Positive OS Trend With Abiraterone and Olaparib in mCRPC But Cites Need for Longer Follow-up

Abiraterone and olaparib continued to demonstrate a positive trend in overall survival (OS) in patients with metastatic castration-resistant prostate cancer, according to Fred Saad, MD, FRCS, though he stated that longer follow-up is needed to confirm the benefit.

Fred Saad, MD, FRCS, a professor and chairman of Urology, and director of Genitourinary Oncology at the University of Montreal Hospital Center, spoke with CancerNetwork® during the 2022 European Society for Medical Oncology Congress (ESMO) about updated findings from the phase 3 PROpel trial (NCT03732820), assessing abiraterone (Zytiga) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC).

In patients who received first-line abiraterone and olaparib or abiraterone and placebo, the median overall survival (OS) was not reached, having achieved a maturity of 40.1% (NR; HR, 0.83; 95% CI, 0.66-1.03; P = .11). Moreover, he described the benefit patients with BRCA mutations experienced after receiving the regimen.

Transcript:

What the data we presented here adds to what has already been presented and published is that as the data mature, we're seeing that this trend in overall survival [OS] continues to improve. [It] is very reassuring that we're not seeing a disappearance of that [OS] advantage; it’s actually getting better as the data continues to mature. We’re still only at [approximately] 40% of deaths. The median survival has still not been reached in either arm, which is a good thing for patients, but it tells us that we need to have more time for definite answers regarding [OS].

It also adds to our understanding of the importance of patients with or without mutations, especially BRCA mutations. For [those] who are still wondering about the actual benefit, this answers several questions. Clearly, BRCA-mutated patients are getting tremendous benefit.

Reference

Saad F, Armstrong AJ, Thiery-Vuillemin A, et al. 1357O - Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2022;33(suppl 7):S616-S652. doi:10.1016/annonc/annonc1070